Michael Riley - SPDR SP Vice President

XBI Etf  USD 128.85  1.50  1.18%   
Michael Riley is Portfolio Manager at SPDR SP Biotech
Michael P. Riley is Principle, State Street Global Advisors Assistant Vice President, State Street Bank and Trust Company .
Age 43
Tenure 21 years
IssuerSSgA
Inception Date2006-01-31
BenchmarkS&P Biotechnology Select Industry Index
Entity TypeRegulated Investment Company
Asset Under Management8.23 Billion
Average Trading Volume9.96 Million
Asset TypeEquity
CategorySector
FocusHealth Care
Market ConcentrationDeveloped Markets

Similar Fund Executives

Found 4 records

One Year Return

Ira ShapiroiShares MSCI Brazil
51
Amy SchioldageriShares MSCI Brazil
55
Matt TuckeriShares MSCI Brazil
N/A
Michael LathamiShares MSCI Brazil
51
In seeking to track the performance of the SP Biotechnology Select Industry Index , the fund employs a sampling strategy. SP Biotech is traded on NYSEARCA Exchange in the United States. SPDR SP Biotech [XBI] is traded in USA and was established 2006-01-31.

SPDR SP Biotech Money Managers

Gary French, Treasurer
John Clark, Assistant Treasurer
Dave Kelly, Independent Trustee
Helen Peters, Independent Trustee
Matthew Flaherty, Assistant Treasurer
Michael Riley, Vice President
Mary Zeven, Secretary
Chad Hallett, Assistant Treasurer of Street tracks series trust
Scott Zoltowski, Assistant Secretary
Peter Ambrosini, Chief Compliance Officer
James Ross, President Trustee
Frank Nesvet, Independent Trustee

SPDR Etf Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is SPDR SP a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether SPDR SP Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SPDR SP's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spdr Sp Biotech Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Spdr Sp Biotech Etf:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in SPDR SP Biotech. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
SPDR SP Biotech's market price often diverges from its book value, the accounting figure shown on SPDR's balance sheet. Smart investors calculate SPDR SP's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since SPDR SP's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between SPDR SP's value and its price as these two are different measures arrived at by different means. Investors typically determine if SPDR SP is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SPDR SP's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.